CN111032084A - 治疗活动性嗜酸性食管炎的方法 - Google Patents

治疗活动性嗜酸性食管炎的方法 Download PDF

Info

Publication number
CN111032084A
CN111032084A CN201880050334.6A CN201880050334A CN111032084A CN 111032084 A CN111032084 A CN 111032084A CN 201880050334 A CN201880050334 A CN 201880050334A CN 111032084 A CN111032084 A CN 111032084A
Authority
CN
China
Prior art keywords
patient
pathway inhibitor
eoe
esophageal
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050334.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·拉丁
J·D·汉密尔顿
L·曼内特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of CN111032084A publication Critical patent/CN111032084A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880050334.6A 2017-08-04 2018-08-03 治疗活动性嗜酸性食管炎的方法 Pending CN111032084A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US62/541,242 2017-08-04
US201762561593P 2017-09-21 2017-09-21
US62/561,593 2017-09-21
EP18305252.1 2018-03-08
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Publications (1)

Publication Number Publication Date
CN111032084A true CN111032084A (zh) 2020-04-17

Family

ID=63113646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050334.6A Pending CN111032084A (zh) 2017-08-04 2018-08-03 治疗活动性嗜酸性食管炎的方法

Country Status (9)

Country Link
EP (1) EP3661551A1 (OSRAM)
JP (2) JP7417515B2 (OSRAM)
KR (2) KR20240152980A (OSRAM)
CN (1) CN111032084A (OSRAM)
AU (2) AU2018311981B2 (OSRAM)
CA (1) CA3071528A1 (OSRAM)
IL (2) IL315556A (OSRAM)
MA (1) MA49744A (OSRAM)
MX (2) MX2020001305A (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208104A1 (zh) * 2022-04-29 2023-11-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115768516A (zh) * 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392497A (zh) * 2013-07-11 2016-03-09 瑞泽恩制药公司 以il-4r抑制剂治疗嗜酸性食管炎的方法
CN105849280A (zh) * 2013-10-23 2016-08-10 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
US20160264658A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited TSLP Binding Proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392497A (zh) * 2013-07-11 2016-03-09 瑞泽恩制药公司 以il-4r抑制剂治疗嗜酸性食管炎的方法
CN105849280A (zh) * 2013-10-23 2016-08-10 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
US20160264658A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited TSLP Binding Proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRÉDÉRIC NICODÈME等: "Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208104A1 (zh) * 2022-04-29 2023-11-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途

Also Published As

Publication number Publication date
JP2020529434A (ja) 2020-10-08
MX2024012777A (es) 2024-11-08
JP7417515B2 (ja) 2024-01-18
IL272245B1 (en) 2024-10-01
KR102719720B1 (ko) 2024-10-22
AU2018311981B2 (en) 2024-11-14
MX2020001305A (es) 2020-03-09
JP2024016237A (ja) 2024-02-06
RU2020109331A3 (OSRAM) 2021-12-28
IL272245B2 (en) 2025-02-01
CA3071528A1 (en) 2019-02-07
KR20240152980A (ko) 2024-10-22
EP3661551A1 (en) 2020-06-10
AU2025200955A1 (en) 2025-03-06
AU2018311981A1 (en) 2020-02-20
IL272245A (en) 2020-03-31
RU2020109331A (ru) 2021-09-06
MA49744A (fr) 2020-06-10
IL315556A (en) 2024-11-01
KR20200035442A (ko) 2020-04-03

Similar Documents

Publication Publication Date Title
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
AU2020200497B2 (en) Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
JP7124040B2 (ja) 抗ｉｌ－１３抗体を使用する、ｉｌ－１３活性が有害である疾患の治療方法
CN115768516A (zh) 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
JP2024016237A (ja) 活動性好酸球性食道炎を治療する方法
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination